| 2024-11-18 | -50.9% | news | Seeking Alpha | Neurogene stock plunges 36% on NGN-401 study update |
| 2024-11-22 | +42.5% | legal | Mugglehead Investment Magazine | Neurogene patient dies in drug trial, stock surges after FDA says ‘use lower dose’ - Mugglehead Investment Magazine |
| 2024-11-11 | -41.1% | news | Seeking Alpha | Neurogene plummets 35% on gene therapy trial data for Rett syndrome |
| 2025-03-31 | -34.5% | legal | Seeking Alpha | How Peter Marks' FDA departure is impacting pharma, biotech stocks |
| 2023-07-18 | -29.6% | M&A | Seeking Alpha | Neoleukin jumps 7% on Neurogene merger |
| 2025-02-04 | +26.8% | news | PR Newswire | INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE - PR Newswire |
| 2025-11-13 | -25.1% | earnings | Seeking Alpha | Neurogene GAAP EPS of -$0.99 |
| 2025-11-13 | -25.1% | news | Seeking Alpha | Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript |
| 2024-11-19 | -23.1% | earnings | Seeking Alpha | Neurogene GAAP EPS of -$1.19 in-line |
| 2024-01-05 | +20.7% | news | Stock Titan | Latest NGNE News - Neurogene Announces Business Update and 202... - Stock Titan |
| 2024-01-05 | +20.7% | news | Stock Titan | Neurogene Announces Business Update and 2024 Outlook - Stock Titan |
| 2025-10-09 | +19.9% | earnings | Stock Titan | 23 developmental milestones — Neurogene to start Embolden dosing in Q4 2025 after FDA talks and ICV data - Stock Titan |
| 2024-03-18 | +18.9% | earnings | Seeking Alpha | Neoleukin Therapeutics reports Q4 results |
| 2026-02-26 | +18.0% | legal | Business Wire | Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome |
| 2026-02-26 | +18.0% | legal | Stock Titan | FDA fast-tracks one-time Rett syndrome gene therapy from Neurogene - Stock Titan |
| 2026-02-26 | +18.0% | legal | TipRanks | Neurogene Gains FDA Breakthrough Status for Rett Gene Therapy - TipRanks |
| 2026-03-03 | +15.5% | news | Stock Titan | Four new Neurogene hires receive options tied to stock price - Stock Titan |
| 2026-03-03 | +15.5% | executive | Stock Titan | Neurogene Inc. (NGNE) CFO sells 4,800 shares under 10b5-1 plan - Stock Titan |
| 2024-11-26 | +15.4% | news | Seeking Alpha | Neurogene and Ventyx Biosciences rises after insider buying by executives |
| 2024-11-26 | +15.4% | news | TradingView | NGNE Stock Price and Chart — NASDAQ:NGNE - TradingView |
| 2025-05-09 | +14.8% | earnings | Seeking Alpha | Neurogene GAAP EPS of -$1.08 misses by $0.02 |
| 2026-04-16 | +14.6% | legal | DirectorsTalk Interviews | Neurogene Inc. (NGNE) Stock Analysis: Exploring a 223% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews |
| 2026-04-16 | +14.6% | news | Stock Titan | Neurogene (NASDAQ: NGNE) 2026 proxy sets director, pay and auditor votes - Stock Titan |
| 2026-03-24 | +13.6% | earnings | Associated Press Finance | Neurogene: Q4 Earnings Snapshot |
| 2026-03-24 | +13.6% | news | Business Wire | Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates |
| 2026-03-24 | +13.6% | earnings | Seeking Alpha | Neurogene GAAP EPS of -$4.24 beats by $0.04 |
| 2026-03-24 | +13.6% | news | Stock Titan | Rett syndrome gene therapy clears 50% dosing, no HLH cases yet - Stock Titan |
| 2026-03-24 | +13.6% | earnings | marketscreener.com | Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com |
| 2024-11-14 | -11.1% | earnings | MarketBeat | Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" - MarketBeat |
| 2025-04-05 | -10.3% | news | Seeking Alpha | Top 10 Russell 2000 weekly gainers and losers as Wall Street crashes |
| 2025-08-11 | -10.3% | earnings | Seeking Alpha | Neurogene GAAP EPS of -$1.05 |
| 2025-08-11 | -10.3% | earnings | Stock Titan | NGNE posts Q2 2025 earnings release and updated corporate presentation - Stock Titan |
| 2025-08-11 | -10.3% | legal | Business Wire | Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire |
| 2023-04-19 | +9.8% | news | Seeking Alpha | Neoleukin Therapeutics: Strategic Review Play |
| 2024-04-17 | -9.5% | analyst | TradingView | NGNE Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-03-17 | -8.5% | executive | Stock Titan | Tax-driven share sale by Neurogene (NGNE) president and CFO disclosed - Stock Titan |
| 2024-05-10 | -7.9% | earnings | Seeking Alpha | Neurogene GAAP EPS of -$1.00 beats by $0.03 |
| 2023-09-22 | +7.1% | news | Seeking Alpha | Neoleukin Therapeutics announces 1-for-5 reverse stock split |
| 2025-04-25 | -6.4% | news | Stock Titan | NGNE Stock Price, News & Analysis - Stock Titan |
| 2026-02-27 | +5.8% | analyst | The Fly | Block upgraded, Duolingo downgraded: Wall Street's top analyst calls |
| 2026-02-27 | +5.8% | analyst | 24/7 Wall St. | Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More |
| 2026-02-27 | +5.8% | legal | Seeking Alpha | Neurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain Cautious |
| 2026-02-27 | +5.8% | legal | Seeking Alpha | Neurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain Cautious - Seeking Alpha |
| 2026-02-27 | +5.8% | analyst | Stocktwits | This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits |
| 2026-02-27 | +5.8% | news | Benzinga | Why Is Neurogene Stock Skyrocketing Friday? - Neurogene (NASDAQ:NGNE) - Benzinga |
| 2026-02-27 | +5.8% | news | Benzinga | 12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga |
| 2026-02-27 | +5.8% | news | Asianet Newsable | Why Did NGNE Stock Surge 25% In Pre-Market Today? - Asianet Newsable |
| 2024-08-09 | -5.6% | earnings | Seeking Alpha | Neoleukin Therapeutics GAAP EPS of -$1.09 misses by $0.07, revenue of $0.93M |
| 2024-07-01 | +4.8% | news | Seeking Alpha | Neurogene to join Russell 3000 Index |
| 2025-02-12 | +4.8% | news | StockInvest.us | NGNE Stock Fundamental Analysis - Financial Scores & Performance Indicators of Neurogene Inc.” - StockInvest.us |
| 2024-11-10 | +4.8% | news | Seeking Alpha | Neurogene: Interesting CNS Disease Company, Data Coming Soon |
| 2026-04-20 | -4.0% | executive | Business Wire | Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors |
| 2026-04-20 | -4.0% | news | Cổng thông tin điện tử Tỉnh Sơn La | Neurogene (NGNE) Stock: Is It Showing Downtrend Signals (Bullish Sentiment) 2026-04-20 - Top Breakouts - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-20 | -4.0% | executive | Stock Titan | Neurogene (NGNE) Chief Commercial Officer listed in new Form 3 - Stock Titan |
| 2026-04-20 | -4.0% | news | Stock Titan | New CCO and board role strengthen Neurogene (NASDAQ: NGNE) leadership - Stock Titan |
| 2026-04-20 | -4.0% | expansion | Stock Titan | Neurogene hires launch chief as Rett syndrome gene therapy moves ahead - Stock Titan |
| 2026-04-20 | -4.0% | news | UBND thành phố Hải Phòng | Neurogene (NGNE) Stock: Is It Showing Downtrend Signals (Bullish Sentiment) 2026-04-20 - Day Trade - UBND thành phố Hải Phòng |
| 2025-03-07 | +3.9% | news | Seeking Alpha | Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401 |
| 2026-03-25 | +3.7% | news | The Globe and Mail | Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway - The Globe and Mail |
| 2026-03-30 | -3.5% | executive | Investing.com | Neurogene (NGNE) president and CFO Cvijic sells $55k in stock - Investing.com |
| 2026-03-30 | -3.5% | executive | Stock Titan | Neurogene (NGNE) CFO’s 2,558-share sale tied to mandatory RSU tax withholding - Stock Titan |
| 2026-03-30 | -3.5% | executive | Stock Titan | Neurogene (NGNE) CEO McMinn logs small, tax-related sale after RSU vesting - Stock Titan |
| 2026-03-30 | -3.5% | news | Stock Titan | RSU tax sale: Neurogene (NGNE) CMO disposes 828 shares - Stock Titan |
| 2023-12-15 | +3.1% | news | Seeking Alpha | Neoleukin Therapeutics announces 1-for-4 reverse stock split |
| 2025-10-05 | +3.0% | news | simplywall.st | Neurogene Insiders Placed Bullish Bets Worth US$1.46m - simplywall.st |
| 2024-02-12 | -3.0% | earnings | MarketBeat | Neurogene (NGNE) Short Interest & Short Float | Updated Apr 2026 - MarketBeat |
| 2024-02-04 | +2.9% | news | ChartMill | NGNE Stock Price, Quote & Chart | NEUROGENE INC (NASDAQ:NGNE) - ChartMill |
| 2024-02-04 | +2.9% | analyst | ChartMill | NGNE Forecast, Price Target & Analyst Ratings | NEUROGENE INC (NASDAQ:NGNE) - ChartMill |
| 2023-12-19 | +2.9% | M&A | Seeking Alpha | Neurogene closes merger with Neoleukin, concurrent private placement |
| 2023-12-19 | +2.9% | executive | Stock Titan | Latest NGNE News - Neurogene Appoints Christy Shafer as Chief ... - Stock Titan |
| 2023-12-26 | +2.1% | earnings | MarketBeat | Neurogene (NGNE) Stock Price, News & Analysis - MarketBeat |
| 2025-03-24 | -2.1% | legal | Seeking Alpha | Neurogene files for $300M mixed securities shelf |
| 2025-03-24 | -2.1% | news | Seeking Alpha | Neoleukin Therapeutics reports FY results |
| 2025-03-24 | -2.1% | news | Stock Titan | Neurogene's $312M War Chest Fuels Promising Rett Syndrome Treatment Progress - Stock Titan |
| 2024-01-12 | +1.8% | news | TradingView | Technical Analysis of Neurogene Inc. (NASDAQ:NGNE) - TradingView |
| 2026-03-11 | -1.7% | news | Business Wire | Neurogene to Participate in Stifel 2026 Virtual CNS Forum |
| 2026-03-11 | -1.7% | news | Stock Titan | Genetic-medicine firm Neurogene in Stifel 2026 virtual CNS fireside chat - Stock Titan |
| 2023-12-20 | -1.6% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2024-06-11 | -1.5% | analyst | Seeking Alpha | Neurogene a new outperform at Baird on gene therapy for Rett syndrome |
| 2024-01-16 | +1.1% | executive | Seeking Alpha | Neurogene names Julie Jordan as chief medical officer |
| 2026-04-22 | +1.1% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | NGNE Neurogene posts narrower Q4 2025 loss than consensus estimates, edges down modestly in today’s trading. - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-11-24 | +1.0% | news | Seeking Alpha | Neurogene: From Speculation To Execution With NGN-401 |
| 2025-11-24 | +1.0% | news | Seeking Alpha | Neurogene: From Speculation To Execution With NGN-401 (NASDAQ:NGNE) - Seeking Alpha |
| 2026-04-08 | -0.9% | news | Business Wire | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-08 | -0.9% | news | Stock Titan | Four new Neurogene hires get options for 69,140 shares - Stock Titan |
| 2026-04-08 | -0.9% | legal | Stock Titan | NGNE SEC Filings - Neurogene 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2026-04-08 | -0.9% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | Why is Neurogene (NGNE) Stock underperforming the market | Price at $22.07, Up 5.55% - Post Earnings - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-03-21 | +0.6% | executive | MarketBeat | Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference |
| 2026-04-06 | +0.5% | earnings | UBND thành phố Hải Phòng | Will Neurogene (NGNE) Stock Miss Expectations | Price at $20.47, Down 1.06% - Company Analysis - UBND thành phố Hải Phòng |
| 2026-04-06 | +0.5% | earnings | Xã Thanh Hà | Will Neurogene (NGNE) Stock Miss Expectations | Price at $20.47, Down 1.06% - Market Signals - Xã Thanh Hà |
| 2024-03-26 | -0.2% | M&A | Seeking Alpha | Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers |
| 2026-02-14 | -0.2% | news | MarketBeat | Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit |
| 2025-05-16 | +0.0% | analyst | Seeking Alpha | Neurogene downgraded to Neutral at Baird on regulatory uncertainty |